A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive

​ Conditions: Muscle-Invasive Bladder Cancer (MIBC)

Interventions: Drug: Durvalumab; Drug: Gemcitabine; Drug: Cisplatin

Sponsors: AstraZeneca

Not yet recruiting Conditions: Muscle-Invasive Bladder Cancer (MIBC)
Interventions: Drug: Durvalumab; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: AstraZeneca
Not yet recruiting